NOTICE is hereby given that Xellera Therapeutics Limited, a company duly incorporated with limited liability under the laws of Hong Kong whose registered office is at Unit 1801, 09–16, 18/F, Millennium City 5, 418 Kwun Tong Road, Kwun Tong, Kowloon, Hong Kong (“Transferor”), which carries on business in biotechnology in Hong Kong under the name and image of “Xellera Therapeutics Limited”, has agreed to sell and transfer its business, including the goodwill thereof, and certain of its assets in Hong Kong (“Business”) to NOVOHEART LIMITED (再心生物科技有限公司), a company duly incorporated with limited liability under the laws of Hong Kong whose registered office is at Unit 1801, 09–16, 18/F, Millennium City 5, 418 Kwun Tong Road, Kwun Tong, Kowloon, Hong Kong (“Transferee”).
After the transfer of the Business, the Transferee intends to continue to carry on the Business at the same address.
The effective date of transfer of the Business is 1 May 2022 (or such later date as the Transferor and the Transferee may agree) subject to all conditions required for completion being satisfied or waived.
NOTICE is hereby given that upon the expiration of one (1) month after the date of the publication of this Notice pursuant to Section 5(3) of the Transfer of Businesses (Protection of Creditors) Ordinance, the liability of the Transferee (if any) for all the debts and obligations arising out of and in relation to the carrying on of the Business by the Transferor shall cease by virtue of the Transfer of Businesses (Protection of Creditors) Ordinance unless proceedings are instituted prior to the expiry of such one (1) month period.
Dated 1 April 2022.
Xellera Therapeutics Limited
Unit 1801, 09–16, 18/F, Millennium City 5, 418 Kwun Tong Road, Kwun Tong, Kowloon, Hong Kong
As Transferor
NOVOHEART LIMITED (再心生物科技有限公司)
Unit 1801, 09–16, 18/F, Millennium City 5, 418 Kwun Tong Road, Kwun Tong, Kowloon, Hong Kong
As Transferee